Concord Drugs Ltd has addressed the discrepancies in the Q1, June 2024 financial results as pointed out by BSE Limited.
The company has provided a Limited Review Report in the SEBI prescribed format.
The review of the financial results was conducted by Pundarikashyam and Associates India Chartered Accountants.
The review was conducted in accordance with the Standard on Review Engagements (SRE) 2410.
The review did not enable the auditor to obtain assurance that would become aware of all significant matters that might be identified in an audit.